Methods for slowing familial ALS disease progression

Details Methods for slowing familial ALS disease progression Methods for slowing familial ALS disease progression

2006-09-21

2009-11-24

Chong, Kimberly (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024310, C536S024100, C536S024500, C435S325000, C435S375000

Reexamination Certificate

active

07622455

ABSTRACT:
Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

REFERENCES:
patent: 5536638 (1996-07-01), Rossau et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5843641 (1998-12-01), Brown et al.
patent: 5849290 (1998-12-01), Brown et al.
patent: 5994076 (1999-11-01), Chenchik et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6077833 (2000-06-01), Bennett et al.
patent: 6194150 (2001-02-01), Stinchcomb et al.
patent: 6352829 (2002-03-01), Chenchik et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6784290 (2004-08-01), Monia et al.
patent: 7132530 (2006-11-01), Bennett et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2002/0156040 (2002-10-01), Oberley et al.
patent: 2005/0019915 (2005-01-01), Bennett et al.
patent: 2006/0229268 (2006-10-01), Benjamin et al.
patent: 2006/0293269 (2006-12-01), Bennett et al.
patent: 2007/0054869 (2007-03-01), Bennett et al.
patent: 2007/0117772 (2007-05-01), Bennett et al.
patent: 9005181 (1990-05-01), None
patent: 9419493 (1994-09-01), None
patent: 9726270 (1997-07-01), None
patent: 9731012 (1997-08-01), None
patent: 0203979 (2002-01-01), None
patent: 02044321 (2002-06-01), None
patent: 03004602 (2003-01-01), None
patent: WO 03/000707 (2003-01-01), None
patent: WO 2005/040180 (2005-06-01), None
Braasch et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry 2002, Vo. 41(14): 4503-4510.
Scanlon, K. Anti-Genes: siRNA, Riboyzmes and Antisense. Current Pharmaceutical Biotechnology 2004, No. 5: 415-420.
Non-final Office Action from U.S. Appl. No. 10/672,866, mail date May 3, 2005.
Non-final Office Action from U.S. Appl. No. 09/888,360, mail date May 21, 2002.
Final Rejection from U.S. Appl. No. 09/888,360, mail date Feb. 11, 2003.
Non-final Office Action from U.S. Appl. No. 10/633,843, mail date Nov. 15, 2005.
Final Rejection from U.S. Appl. No. 10/633,843, mail date Apr. 5, 2006.
Notice of Allowance from U.S. Appl. No. 10/633,843, mail date Jul. 3, 2006.
Non-final Office Action from U.S. Appl. No. 11/449,207, mail date Feb. 12, 2007.
Agrawal, S. et al., “Antisense therapeutics: is it as simple as complementary base recognition?” Mol. Med. Today (2000) 6:72-81.
Al-Chalabi, A. et al., “Recent advances in amyotrophic lateral sclerosis,” Curr. Opin. Neurol. (2000) 13:397-405.
Alisky, J. M. et al., “Gene Therapy for Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases,” Human Gene Therapy (2000) 11:2315-2329.
Berger, M. et al., “Universal bases for hybridization, replication and chain termination,” Nucleic Acids Research (2000) 28(15):2911-2914.
Branch, A. D., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Brooks, B. R. et al., “El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis,” ALS and other motor neuron disorders (2000) 1:293-299.
Bruijn, L. I. et al., “Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1,” Science (1998) 281:1851-1854.
Cleveland, D. W. et al., “Oxidation versus aggregation—how do SOD1 mutants cause ALS?” Nature Medicine (2000) 6(12):1320-1321.
Crooke, S. T., “Basic Principles of Antisense Therapeutics,” Antisense Research and Application (1998) Springer-Verlag, New York, pp. 1-50.
Fridovich, I., “Superoxide Radical and Superoxide Dismutases,” Annu. Rev. Biochem. (1995) 64:97-112.
Green, D. W. et al., “Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease,” J. Am. Coll. Surg. (2000) 191(1):93-105.
Grzanna, R. et al., “Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects,” Molecular Brain Research (1998) 63:35-52.
Gulesserian, T. et al., “Superoxide Dismutase SOD1, Encoded on Chromosome 21, but not SOD2 is Overexpressed in Brains of Patients with Down Syndrome,” J. Investig. Med. (2001) 49:41-46.
Hammond, S. M. et al., “Post-Transcriptional Gene Silencing by Double-Stranded RNA,” Nature (2001) 2:110-119.
Hottinger, A. F. et al., “The Copper Chelator d-Penicillamine Delays Onset of Disease and Extends Survival in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis,” Eur. J. Neurosci. (1997) 9:1548-1551.
Huang, P. et al., “Superoxide dismutase as a target for the selective killing of cancer cells,” Nature (2000) 407:390-395.
Jen, K.-Y. et al., “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” Stem Cells (2000) 18:307-319.
Kawata, A. et al., “Aberrant splicing of human Cu/Zn superoxide dismutase (SOD1) RNA transcripts,” NeuroReport (2000) 11:2649-2653.
Klivenyi, P. et al., “Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis,” Nature Medicine (1999) 5(3):347-350.
Lee W. G. et al. “Molecular Cloning and High-Level Expression of Human Cytoplasmic Superoxide Dismutase Gene inEscherichia coli,” Kor. J. Microbiol. (1990) 28(2):91-97.
Milner, N. et al., “Selective effective antisense reagents on combinatorial oligonucleotide arrays,” Nature Biotechnology (1997) 15:537-541.
Misra, A. et al., “Drug delivery to the central nervous system: a review,” J. Phar. Pharmaceut. Sci. (2003) 6 (2):6384-6387.
Muramatsu, H. et al., “Superoxide Dismutase in SAS Human Tongue Carcinoma Cell Line is a Factor Defining Invasiveness and Cell Motility,” Cancer Research (1995) 55:6210-6214.
Rothstein, J. D. et al., “Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons,” Proc. Natl. Acad. Sci. USA (1994) 91:4155-4159.
Rowland, L. P., “Six important themes in amyotrophic lateral sclerosis (ALS) research, 1999,” J. Neurol. Sci. (2000) 180:2-6.
Sanghvi, Y. S., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides,” Antisense Research and Applications (1993) CRC Press, Boca Raton, pp. 276-278.
Skerra, A., “Phosphorothioate primers improve the amplification of DNA sequences by DNA polymerases with proofreading activity,” Nucleic Acids Research (1992) 20(14):3551-3554.
Trotti, D. et al., “SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter,” Nature Neuroscience (1999) 2(5):427-433.
Troy, C. M. et al., “Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells,” Proc. Natl. Acad. Sci. USA (1994) 91:6384-6387.
Troy, C. M. et al., “Downregulation of Cu/Zn Superoxide Dismutase Leads to Cell Death via the Nitric Oxide-Peroxynitrite Pathway,” J. Neurosci. (1996) 16(1):253-261.
Dean et al. Antisense oligonucleotide-based therapeutics for cancer. Oncogene, 2003 vol. 22:9087-9096.
Berger, I., et al., “Crystal structures of B-DNA with incorporated 2′-deoxy-2′-fluoro-arabino-furanosyl thymines: implications of conformational preorganization for duplex stability,”Nucleic Acids Res. (1998) 26(10):2473-80.
Dean et al., “Antisense Oligonucleotide-based Therapeutics for Cancer,”Oncogene(2003) 22:9087-9096.
Klug et al.European Journal of Physiology. (2001) 441(6): R205. Abstract No. P20-7.
PCT International Search Report for PCT/US2004/031673 dated Aug. 22, 2005.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oli

Affiliated with

Also associated with

Rating

Methods for slowing familial ALS disease progression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for slowing familial ALS disease progression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for slowing familial ALS disease progression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4133628